MERTK

MERTK Molekülinformation

Englischer Name	Tyrosine-protein kinase Mer	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8	Target-Alias	EC 2.7.10，MER，MERTK，C-Mer Proto-Oncogene Tyrosine Kinase，Receptor Tyrosine Kinase MerTK，Tyrosine-Protein Kinase Mer，EC 2.7.10.1，STK Kinase，EC:2.7.10.1，Proto-oncogene c-Mer，MER Proto-Oncogene， Tyrosine Kinase，MER Receptor Tyrosine Kinase，Tyro12，C-Eyk，C-Mer，RP38，c-Mer Tyrosine Kinase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Tyrosine-protein kinase Mer
Target-Alias	EC 2.7.10，MER，MERTK，C-Mer Proto-Oncogene Tyrosine Kinase，Receptor Tyrosine Kinase MerTK，Tyrosine-Protein Kinase Mer，EC 2.7.10.1，STK Kinase，EC:2.7.10.1，Proto-oncogene c-Mer，MER Proto-Oncogene， Tyrosine Kinase，MER Receptor Tyrosine Kinase，Tyro12，C-Eyk，C-Mer，RP38，c-Mer Tyrosine Kinase
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Approved

MERTK Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Human (2)Mouse (2)Cynomolgus (1)
Etikett
His Tag (2)Fc Tag (3)
Marker
Unconjugated (5)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT MEK-H5253	Human	HEK293	Human MERTK / Mer Protein, Fc Tag	In den Warenkorb legen
HOT MEK-H52H6	Human	HEK293	Human MERTK / Mer Protein, His Tag	In den Warenkorb legen
HOT MEK-M52H9	Mouse	HEK293	Mouse MERTK / Mer Protein, His Tag (MALS verified)	In den Warenkorb legen
MEK-M5253	Mouse	HEK293	Mouse MERTK / Mer Protein, Fc Tag (MALS verified)	In den Warenkorb legen
MEK-C5253	Cynomolgus	HEK293	Cynomolgus MERTK / Mer Protein, Fc Tag (MALS verified)	In den Warenkorb legen

Gesamtmenge5

MERTK Molekülhintergrund

Tyrosine-protein kinase Mer(MERTK) is a member of the TYRO3/AXL/MER (TAM) receptor kinase family and encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains, and one tyrosine kinase domain. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.

MERTK Molekülalias

MERTK,Mer

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Sitravatinib	MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516	Phase 3 Clinical	Mirati Therapeutics Inc	Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma	Details
MRX-2843	UNC-2371; UNC-2025; MRX-2843	Phase 2 Clinical	University Of North Carolina At Chapel Hill	Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplastic Processes; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours	Details
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours	Details
Tamnorzatinib	ONO-7475	Phase 2 Clinical	Ono Pharmaceutical Co Ltd	Carcinoma, Non-Small-Cell Lung; Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancreatic Neoplasms; Solid tumours	Details
Adrixetinib	Q-702	Phase 2 Clinical	Lead Discovery Center GmbH, Max Planck Institute of Biochemistry, Vichem Chemie	Blastic Plasmacytoid Dendritic Cell Neoplasm; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Erdheim-Chester Disease; Esophageal Neoplasms; Graft vs Host Disease; Hematologic Neoplasms; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Lymphoma, Follicular; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Neoplasms, Plasma Cell; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms; Waldenstrom Macroglobulinemia	Details
INCB-081776	INCB-81776; INCB-081776	Phase 1 Clinical	Incyte Corp	Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
Nifitinib Tosilate		Phase 1 Clinical	Sichuan University, Yangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical Co Ltd	Carcinoma, Non-Small-Cell Lung	Details
NPS-1034	HOPE-777; KDDF-201111-02		Neopharma Ltd		Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Cabozantinib S-malate	XL-184; BMS-907351; RO7047650; RO-7047650	Approved	Exelixis Inc	Cometriq, Cabometyx	United States	Thyroid Neoplasms; Carcinoma, Neuroendocrine	Exelixis Inc	2012-11-29	Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin	Details